Halozyme Therapeutics | HALO - 贷款资金



金融业
股票价格
USD
资产
USD 2.58B
现金及等价物
USD 163.14M
销售成本
USD 108.68M
流动资产
USD 933.02M
流动负债
USD 344.44M
债务
USD 2.14B
EBIT
USD -63.72M
EBITDA
USD 328.81M
员工
350
EPS每股收益
USD 2.28
股本和储备
USD 143.54M
销售毛利
USD 297.47M
债务利息支出
USD 5.59M
贷款资金
USD 1.94B
市值
USD 10.91B
净收入
USD 229.91M
营业费用
USD 193.35M
营业利润
USD -63.72M
普通股股本
USD 114.04M
PE价格收益
12.51
税前利润
USD 180.33M
销售收入
USD 481M
销售和管理费用
USD 57M
股票
USD 137.14M
贸易债权人
USD 23.61M
应收帐款人
USD 453.33M


贷款资金 更改 日
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
Amgen USD 51.86B 27M 2026-06
Baxter International USD 8.62B 6M 2026-06
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 248.2M 993K 2026-06
DBV Technologies USD 0 0 2025-03
Eli Lilly USD 47.86B 8.49B 2026-06
Halozyme Therapeutics USD 1.94B 1.79M 2026-06
Intrexon USD 0 198.67M 2024-06
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
MannKind USD 545.13M 2.93M 2026-06
Minerva Neurosciences USD 0 86.58M 2024-09
Nektar Therapeutics USD 60.27M 2.89M 2026-03
Pfizer USD 60.5B 70M 2026-06
Rigel Pharmaceuticals USD 0 0 2024-09
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12